BMS-Celgene Press Releases

Bristol-Myers and Celgene's Liso-Cel

• With Bristol-Myers Squibb's acquisition of Celgene, the former was able to also acquire the "CAR-T therapy lisocabtagene maraleucel (liso-cel)" medication.
• BMS stated that they got positive results for this medication from three studies.
• The announcement was made during the American Society of Hematology (ASH) Annual Meeting.

BMS Investors' Bet

• After the acquisition, BMS investors lobbied for a separately-traded contingent value right (CVR).
• However, the CVR will only be beneficial if three highly promising medications will be released for sale.
• This is then considered as a high-risk stake.

OTEZLA Divestiture

• BMS has made it known that Celgene has reached a deal with Amgen.
• Under the deal, the global license for OTEZLA® (apremilast) will be bought by Amgen for $13.4 billion.
• This is linked to the acquisition of Celgene by BMS.
• BMS has stated in the past that it has decided to sell off OTEZLA as part of an ongoing regulatory approval procedure.